Imarsa

Fulvestrant, the active ingredient in Imarsa, is a selective estrogen receptor degrader (SERD) presented as an intramuscular injection for intramuscular use. It treats hormone receptor‑positive metastatic breast cancer in adult patients. GNH USA supplies Imarsa as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Fulvestrant acts on estrogen‑dependent breast cancer pathways and is indicated for the following conditions: - Hormone receptor‑positive metastatic breast cancer: delays disease progression and improves survival. - Postmenopausal estrogen receptor‑positive advanced breast cancer: used after progression on prior endocrine therapy. - Advanced breast cancer after aromatase‑inhibitor failure: provides an alternative hormonal treatment option.

Fulvestrant may cause a range of adverse reactions.

Common Side Effects: - Injection site pain: discomfort at the intramuscular injection site. - Hot flashes: transient episodes of warmth and sweating. - Nausea: mild to moderate upset stomach. - Fatigue: generalized tiredness. - Headache: mild to moderate intensity. - Musculoskeletal pain: aches in joints or muscles.

Serious or Rare Side Effects: - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Pulmonary embolism: sudden shortness of breath or chest pain. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Tumor pain flare: worsening of cancer‑related pain. - Hyperglycemia: increased blood glucose levels. - Thrombocytopenia: reduced platelet count.

When prescribing or handling Fulvestrant, consider the following precautions: - Monitor liver function: obtain baseline and periodic liver enzyme tests. - Assess thromboembolic risk: evaluate history of clotting disorders before use. - Evaluate hypersensitivity: discontinue if signs of severe allergic reaction appear. - Avoid in uncontrolled infection: postpone treatment until infection is resolved. - Pregnancy considerations: safety unknown; avoid use in pregnant women. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fulvestrant may interact with other medicines.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce fulvestrant exposure. - Concurrent estrogen therapy: can antagonize fulvestrant’s anti‑estrogen effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Other SERDs or hormonal agents: may increase toxicity risk.